aren't MSB seeking approval from FDA with this?
Mesoblast Chief Medical Officer Dr Fred Grossman said: “We expect the mortality benefit observed in
this seminal Phase 3 trial will support a potential path for approval of rexlemestrocel-L in patients with
advanced chronic heart failure. We are planning to meet and discuss potential pathways to approval
based on mortality reduction with the United States Food and Drug Administration.”
aren't MSB seeking approval from FDA with this?Mesoblast Chief...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.030(1.90%) |
Mkt cap ! $1.832B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.59 | $6.078M | 3.759M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 31734 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 880 | 4 |
View Market Depth
| Last trade - 15.12pm 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |